www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

   
  home feedback about us  
   
CHINAGATE.OPINION.Population    
Agriculture  
Education&HR  
Energy  
Environment  
Finance  
Legislation  
Macro economy  
Population  
Private economy  
SOEs  
Sci-Tech  
Social security  
Telecom  
Trade  
Transportation  
Rural development  
Urban development  
     
     
 
 
China can lead new fight in war on AIDS


2004-05-18
China Daily

China's leaders have made significant strides in publicizing official HIV/AIDS policy in recent months.

On World AIDS Day, the media was filled with images of Premier Wen Jiabao and Health Minister Wu Yi visiting AIDS patients. A few weeks later Wu Yi visited the so-called "AIDS villages" in Central China's Henan Province, some of which have an infection rates as high as in sub-Saharan Africa.

Last week, we heard about a series of tough new measures being put in place by the new State Council Co-ordinating Committee on HIV/AIDS, measures aimed at preventing the spread of HIV, as well as providing care and treatment for those already infected.

These are powerful statements from the leadership.

As one health official in Beijing put it: "This is what we have all been waiting for."

The government's new attitude is more than just symbolic. Wen and senior health officials announced a "Four Free" policy in poor and rural areas: free testing; free treatment; free school for "AIDS orphans;" and free treatment to prevent mother-to-child transmission of HIV.

If this new policy can be enacted, China will go from having one of the most closed HIV/AIDS policies in Asia to having one of the best such policies in the world.

The big question now is not whether Chinese leaders want to implement these changes - they clearly do - but how to make them a reality.

They face huge problems. China's healthcare system is inadequate, and the marketization of healthcare over the past two decades means doctors and hospitals now largely rely on drug sales for their livelihood. No money, no treatment.

If HIV/AIDS treatment is to be different, doctors will have to be convinced to put the health of AIDS patients before their own profits, and to overcome their fear of treating AIDS patients.

But one of the greatest obstacles China is facing - and one you rarely see mentioned in the headlines - is the stubborn refusal of foreign pharmaceutical companies to make anti-retroviral drugs available at an affordable price in China.

For example, GSK has patented and registered its drug Epivir (r) (also known as Lamivudine or 3TC) in China, but does not actually market it. (3TC is cheap and has far fewer side-effects than other treatments, and for this reason is the backbone of the WHO's "first-line" HIV/AIDS treatment plan worldwide.) GSK doesn't sell Epivir(r), but does sell the same chemical component in a different dosage under the name Heptodin (r) (to treat hepatitis), but at a very high price.

It sells a combination pill, Combivir(r) (3TC plus another drug, AZT), but at almost US$250 per month,so very few Chinese can afford it. Indeed, US$250 would buy more than a year's supply of an equivalent generic in India.

Why is GSK so reluctant? Market surveys show that Heptodin (r) is GSK's best selling drug in China, accounting for somewhere between US$60-80 million in annual sales. But this is business, and it would be unrealistic to expect companies not to make a profit. Still, what multinational pharmaceutical companies are doing in China is anything but healthy competition. Even if the companies lower their prices for anti-AIDS drugs - something they've been talking about for years now - there are likely to be many restrictions on those "discount" prices.

There is a better solution, however. Under the World Trade Organization (WTO) rules, China has the legal right to issue a compulsory licence and produce copies of GSK's patented medicine. They may fear this would be seen as just another case of the Chinese Government failing to respect patents, and that trade officials from Washington and London would protest strongly. On the contrary, in the words of a WHO report on the subject: "If China chooses to proceed with the issuance of compulsory licenses for some essential medicines, it will be showing its commitment to the patent system...rather than ignoring patents or engaging in underground counterfeiting..."

China should now go ahead with such a decision, and set a bold precedent in international trade. China has the technical capacity to supply not only the domestic market but the world's developing countries with cheap, life-saving AIDS drugs.

For years people have spoken of the time when China takes its rightful place in the world of trading nations.

Now it's time for that to become a reality.

 
 
     
  print  
     
  go to forum  
     
     
 
home feedback about us  
  Produced by m.orobotics.cn. All Rights Reserved
E-mail: webmaster@chinagate.com.cn
主站蜘蛛池模板: 黄色三级三级三级 | 亚洲视频国产视频 | 美女张开腿 | 日日操干 | 欧美国产成人免费观看永久视频 | 精品视频h| 中国胖女人一级毛片aaaaa | 精品久久久久久久久久香蕉 | 毛片1毛片2毛片3毛片4 | 国产香蕉在线视频一级毛片 | 国内自拍在线 | 国产色手机在线观看播放 | 美女黄视频网站 | 欧美综合视频在线观看 | 欧美巨大video粗暴 | 亚洲日本欧美产综合在线 | 亚洲成人高清在线 | 久久国产精品久久久久久久久久 | 国产成人毛片毛片久久网 | 一级做a爰片久久毛片唾 | 欧美亚洲另类在线 | 亚洲乱码一区二区三区国产精品 | 欧美特黄一片aa大片免费看 | 99久久精品免费看国产四区 | 国产精品午夜国产小视频 | 日韩亚洲一区中文字幕在线 | 久热精品6| 中文字幕一二三区 | 欧美亚洲中日韩中文字幕在线 | 国产一级强片在线观看 | 国产精品手机视频一区二区 | 亚洲成年人专区 | 亚洲手机国产精品 | 欧美一级二级毛片视频 | 亚洲综合亚洲综合网成人 | 日本三片在在线播放 | 国产成人精品系列在线观看 | 日本免费人成在线网站 | 免费一级毛片在线观看 | 男人的天堂久久精品激情 | 三级中文字幕永久在线视频 |